All In Biotech

Free tool

FAERS Monitor: Hemiclor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218647 or its brand name (Hemiclor, Chlorthalidone). Reports on generic versions are filed under their own applications.

Reports

11,713

Serious

7,364

63% of reports

Hospitalization

3,734

Death reported

704

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue916
  • nausea758
  • drug ineffective755
  • diarrhoea700
  • dizziness590
  • pain567
  • off label use561
  • headache556
  • dyspnoea532
  • acute kidney injury474
  • chronic kidney disease459
  • arthralgia458
  • asthenia445
  • hypertension406
  • blood pressure increased398

Reports by year received

View as table
YearReports
200432
200540
200660
200744
200868
200986
2010127
2011167
2012215
2013218
2014343
2015533
2016661
2017612
2018784
2019941
2020884
2021953
20221,061
20231,007
20241,051
20251,133
2026693

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,446 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal45910.910.04,111
acute kidney injurySignal4745.65.11,783
blood pressure increasedSignal3984.74.31,155
hypertensionSignal4063.43.1709
astheniaSignal4452.11.9269
dizzinessSignal5902.12.0359
fatigueSignal9162.12.0557
arthralgia4582.01.8225
diarrhoea7001.91.8332
nausea7581.71.6237
dyspnoea5321.71.6153
pain5671.71.5152
headache5561.61.5126
off label use5611.21.111
drug ineffective7551.01.01

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.